Premium
Predominance of pre‐S1 mutated hepatitis B virus in a patient following treatment with adefovir dipivoxil
Author(s) -
Villa Erica,
Boarino Valentina,
Grottola Antonella,
Gelmini Roberta,
Lama Nicole G.
Publication year - 2003
Publication title -
liver transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.814
H-Index - 150
eISSN - 1527-6473
pISSN - 1527-6465
DOI - 10.1053/jlts.2003.50028
Subject(s) - adefovir , virology , hepatitis b virus , wild type , mutant , lamivudine , polymerase chain reaction , polymerase , virus , mutation , biology , medicine , dna , gene , genetics
A liver transplant recipient reinfected with a lamivudine‐resistant mixed wild‐type/pre‐S1–deleted hepatitis B virus (HBV) strain and rescued with adefovir dipivoxil was still HBV DNA positive after more than 1 year of therapy. Analysis of serum HBV DNA, amplified by polymerase chain reaction and directly sequenced by dideoxy nucleotide chain‐termination method, showed that adefovir inhibited the wild type, but not the pre‐S1–deleted HBV. Predominance of the pre‐S1–deleted strain over wild type after adefovir treatment suggests that either adefovir inhibited the wild type more effectively or the pre‐S1 mutant replicates more efficiently. The normality of liver condition confirms that to exert its pathogenic effect, the pre‐S1–deleted strain requires the presence of wild‐type virus